The value of the PCTRF comparative outcomes data

The “New” Prostate Cancer InfoLink wants to be clear for our readers that we are significantly less enthusiastic than others about some of the information being offered to patients, clinicians, and payers through the web site of an organization known as the Prostate Cancer Treatment Research Foundation (PCTRF). … READ MORE …

Can galeterone show effectiveness in men with AR-V7 mCRPC?

According to a report in The ASCO Post last night, the investigational drug galeterone may have significant clinical activity against a specific subtype of castration-resistant prostate cancer (CRPC) known as AR-V7. … READ MORE …

Should we debulk the primary tumor in some men with metastatic prostate cancer?

Back in the 1980s, it would never (well, probably nearly never) have crossed anyone’s mind to carry out any type of primary tumor-debulking treatment on any patient who was newly diagnosed with evident, metastatic prostate cancer. … READ MORE …

Does treatment for prostate cancer lead to PTSD (for at least some men)?

The following two statements appear on the web site of the Mayo Clinic under the definition of post-traumatic stress disorder: … READ MORE …

Focal therapy today: upsides and downsides

While there is considerable allure to the theory behind focal therapy (and focal laser therapy or FLA in particular) as a treatment for some men with localized prostate cancer, it is worth understanding that there are good reasons to consider this allure with great caution. … READ MORE …

The Prostate Health Cocktail in management of biochemically recurrent prostate cancer

A newly published paper by some highly regarded researchers provides data from a small, Phase II trial of Prostate Health Cocktail (PHC) — an “over-the-counter” combination herbal supplement — in the management of biochemical recurrence of prostate cancer. … READ MORE …

Factors in the sequencing of late-stage prostate cancer treatments

A paper in the International Journal of Cancer offers information on the sequencing of cabazitaxel (CAB) and abiraterone acetate (ABI) in men with metastatic, castration-resistant prostate cancer (mCRPC) who have already progressed after treatment with docetaxel. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,169 other followers